Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OnePoint Patient Care shifts Oklahoma facility
The new pharmacy, which is located in Yukon, will reportedly allow it to better serve its existing hospice partners in the Oklahoma City area and give it the
The new pharmacy, which is located in Yukon, will reportedly allow it to better serve its existing hospice partners in the Oklahoma City area and give it the
Teva’s proprietary budesonide product is currently marketed in Italy under the tradename Xavin for the treatment of asthma. Budesonide is a corticosteroid which has been used for more
The court has ruled that BrainLAB was entitled to recover the amount from Medtronic and its law firm McDermott, Will & Emery. The patent infringement lawsuit filed by
Additionally, the company has amended the standstill agreement with Efficacy Capital to permit Efficacy Capital to own up to 40% of the company’s outstanding shares of stock and
Under the terms of the agreement, Wyeth made an up-front equity investment in Advanced Life Sciences through the purchase of common stock representing approximately 4.9% of the company’s
The 10mg/ml strength joins Bioniche’s current offering of Ketamine in 50mg/ml and 100mg/ml strengths and completes its full product line offering. Bioniche plans to launch the 10mg/ml strength
CodeLink activated slides use SurModics’s PhotoLink technology to create a three-dimensional matrix that allows the attachment of biomolecules to form microarrays. Bruce Barclay, president and CEO of SurModics,
If approved, Pharmaxis will be authorized to market Bronchitol in Australia for the treatment of bronchiectasis. The application is based on a multicentre Phase III clinical trial involving
BioChemics (BCI) has developed a novel, transdermal drug delivery system called Vale (vaso-active lipid encapsulated), that allows a wide variety of actives to be delivered into the skin.
This use of once-daily Reyataz boosted with ritonavir (Reyataz/r) in HIV-1 infected treatment-naive adult patients is based on 48-week results from the Castle study, which demonstrated similar antiviral